RIGL Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
Rigel Pharmaceuticals Inc had $294M of revenue in fiscal 2025, up 64.1% on the year before. Over five years, revenue changed +22.1% a year on average.
Last close Β· Oct 23, 2026
$48.13
1.5%Hi! I read Rigel Pharmaceuticals Incβs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+64.1%
Yes. Sales grew 64.1% last year.
Does it make a profit?
124.7%
Yes. It keeps 124.7% of every sale as profit.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
6 / 9
Mixed. It passes 6 of 9 health tests.
How is the share priced?
2.8x
One share costs 2.8 times its yearly profit per share.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Rigel Pharmaceuticals Inc did it, and the next one. Share prices often move a lot on those days.
Next results
November 3, 2026
Tuesday Β· in 8 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 4, 2026 | Q2 '26 | After the market closes | 8-K β |
| May 5, 2026 | Q1 '26 | After the market closes | 8-K β |
| Jan 12, 2026 | Q4 '25 | Before the market opens | 8-K β |
| Nov 4, 2025 | Q3 '25 | After the market closes | 8-K β |
| Aug 5, 2025 | Q2 '25 | After the market closes | 8-K β |
| May 6, 2025 | Q1 '25 | After the market closes | 8-K β |
| Jan 13, 2025 | Q4 '24 | Before the market opens | 8-K β |
| Nov 7, 2024 | Q3 '24 | After the market closes | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Rigel Pharmaceuticals Inc had $294M of revenue in fiscal 2025, up 64.1% on the year before. Over five years, revenue changed +22.1% a year on average. Its operating margin was 42.6%, up 29.1Β pts: of every 100 in sales, about 43 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Rigel Pharmaceuticals Inc made $367M of net profit in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
KIRA Β· Rigel Pharmaceuticals Inc has $102M more cash than debt.
Cash, debt and the ratios that show how comfortably Rigel Pharmaceuticals Inc can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $125M | $58.2M | $56.9M | $77.3M | $155M |
| Debt incl. finance leases | $20.0M | $40.0M | $60.0M | $60.0M | $52.5M |
| Net debt / EBITDA | β | β | β | β0.7x | β0.8x |
| Debt / equity | 0.7x | β | β | 18.2x | 0.1x |
| Interest coverage | β2.6x | β15.0x | β3.0x | 3.1x | 17.1x |
| Current ratio | 2.4x | 1.8x | 1.9x | 2.1x | 2.4x |
| Quick ratio | 2.3x | 1.6x | 1.8x | 2.0x | 2.3x |
| Total assets | $167M | $134M | $117M | $164M | $514M |
| Total liabilities | $137M | $148M | $146M | $161M | $122M |
| Shareholders' equity | $30.4M | β$13.6M | β$28.6M | $3.3M | $391M |
| Net debt (β = net cash) | β$105M | β$18.2M | $3.1M | β$17.3M | β$102M |
KIRA Β· Its return on capital was 43.4%: every 100 invested in the business earned about 43 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Rigel Pharmaceuticals Inc passes 6 of 9 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 3 / 7 | 3 / 7 | 3 / 8 | 4 / 9 | 6 / 9 | 2 / 9 | 4 / 9 | 7 / 9 | 6 / 9 |
| Accruals ratio | 8.5% | β0.4% | β9.0% | β17.7% | 17.4% | β17.1% | 10.1% | β15.4% | β9.9% | 86.0% |
| Altman Z'' | β43.26 | β24.48 | β22.75 | β28.03 | β37.01 | β22.50 | β33.96 | β37.95 | β23.75 | 0.31 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $20.4M | $4.5M | $44.5M | $59.3M | $109M | $149M | $120M | $117M | $179M | $294M |
| Gross profit | β | β | $44.2M | $58.4M | $108M | $148M | $118M | $110M | $161M | $275M |
| Research and development | $63.4M | $46.3M | $46.9M | $52.9M | $60.1M | $65.2M | $60.3M | $24.5M | $23.4M | $33.3M |
| Operating income | β$69.7M | β$79.6M | β$72.7M | β$69.1M | β$29.0M | β$12.5M | β$55.6M | β$20.5M | $24.2M | $125M |
| Interest expense | β | β | β | $0.3M | $1.4M | $4.9M | $3.7M | $6.9M | $7.9M | $7.3M |
| Pretax income | β | β | β | β$66.9M | β$29.7M | β$17.3M | β$58.6M | β$25.1M | $18.4M | $122M |
| Income tax | $0.0M | $0.0M | $0.0M | β | β | $0.6M | β | $0.0M | $0.9M | β$245M |
| Net income | β$69.2M | β$78.0M | β$70.5M | β$66.9M | β$29.7M | β$17.9M | β$58.6M | β$25.1M | $17.5M | $367M |
| Net income to common | β$69.2M | β$78.0M | β$70.5M | β$66.9M | β$29.7M | β$17.9M | β$58.6M | β$25.1M | $17.5M | $367M |
| Diluted EPS | β$0.73 | β$0.62 | β$0.44 | β$0.40 | β$0.18 | β$0.11 | β$3.44 | β$1.44 | $0.99 | $19.48 |
| Diluted shares | 0.09B | 0.13B | 0.16B | 0.17B | 0.17B | 0.17B | 0.02B | 0.02B | 0.02B | 0.02B |
| Cash flow | ||||||||||
| Cash from operations | β$75.9M | β$77.6M | β$58.8M | β$41.5M | β$52.2M | $5.9M | β$73.8M | β$5.7M | $31.5M | $75.7M |
| Capital expenditure | $0.8M | $0.2M | $1.1M | $1.5M | $1.3M | $0.6M | $0.5M | β | β | β |
| Free cash flow | β$76.7M | β$77.7M | β$59.9M | β$43.0M | β$53.4M | $5.3M | β$74.2M | β | β | β |
| Depreciation and amortization | $0.9M | $0.5M | $0.6M | $0.7M | $0.7M | $1.2M | $1.0M | $1.2M | $2.2M | $2.4M |
| Stock-based compensation | $7.3M | $6.0M | $7.7M | $9.1M | $7.3M | $9.5M | $12.4M | $8.8M | $12.4M | $12.7M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $74.8M | $116M | $129M | $98.1M | $57.3M | $125M | $58.2M | $56.9M | $77.3M | $155M |
| Total debt | β | β | β | $10.0M | $20.0M | $20.0M | $40.0M | $60.0M | $60.0M | $52.5M |
| Current assets | $76.2M | $117M | $137M | $119M | $89.0M | $154M | $116M | $99.3M | $135M | $240M |
| Current liabilities | $22.6M | $18.3M | $27.7M | $58.2M | $40.8M | $63.6M | $65.2M | $53.3M | $63.3M | $99.2M |
| Inventory | β | β | $0.9M | $1.4M | $1.6M | $6.6M | $9.1M | $5.5M | $6.0M | $11.5M |
| Property and equipment, net | $1.2M | $0.9M | $1.4M | $2.2M | $2.7M | $2.2M | $0.9M | $0.2M | $0.1M | $0.0M |
| Intangible assets | β | β | β | β | β | β | $14.9M | $13.9M | $27.1M | $24.7M |
| Total assets | $78.1M | $119M | $139M | $148M | $110M | $167M | $134M | $117M | $164M | $514M |
| Total liabilities | $23.1M | $18.5M | $29.2M | $93.8M | $76.4M | $137M | $148M | $146M | $161M | $122M |
| Preferred stock | β | β | β | β | β | β | β | β | $0.0M | $0.0M |
| Shareholders' equity | $55.0M | $101M | $110M | $53.8M | $34.0M | $30.4M | β$13.6M | β$28.6M | $3.3M | $391M |
| Margins | ||||||||||
| Gross margin | β | β | 99.4% | 98.5% | 99.2% | 99.3% | 98.5% | 93.9% | 89.6% | 93.3% |
| Operating margin | β342.2% | β1,775.6% | β163.3% | β116.5% | β26.7% | β8.4% | β46.2% | β17.5% | 13.5% | 42.6% |
| EBITDA margin | β337.5% | β1,765.2% | β162.0% | β115.4% | β26.0% | β7.6% | β45.4% | β16.5% | 14.7% | 43.5% |
| Net margin | β339.6% | β1,739.3% | β158.4% | β112.8% | β27.4% | β12.0% | β48.7% | β21.5% | 9.8% | 124.7% |
| FCF margin | β376.3% | β1,733.3% | β134.7% | β72.5% | β49.2% | 3.5% | β61.7% | β | β | β |
| Returns | ||||||||||
| Return on capital | β | β | β | β | β | β | β | β | β | 43.4% |
| Return on capital employed | β125.6% | β79.0% | β65.3% | β77.3% | β41.7% | β12.0% | β80.4% | β32.0% | 24.0% | 30.3% |
| Return on equity | β125.8% | β100.2% | β67.0% | β81.7% | β67.7% | β55.6% | β699.0% | β | β | 185.9% |
| Return on assets | β88.6% | β79.1% | β54.6% | β46.7% | β23.1% | β12.9% | β38.8% | β20.0% | 12.4% | 108.3% |
| Return on tangible equity | β125.8% | β77.5% | β64.1% | β124.3% | β87.4% | β59.0% | β | β | β | 100.1% |
| Growth | ||||||||||
| Revenue growth | β | β78.0% | 892.6% | 33.2% | 83.2% | 37.4% | β19.4% | β2.8% | 53.4% | 64.1% |
| Net income growth | β | β | β | β | β | β | β | β | β | 1,999.1% |
| EPS growth | β | β | β | β | β | β | β | β | β | 1,867.7% |
| FCF growth | β | β | β | β | β | β | β1,513.2% | β | β | β |
| Share count change | β | 33.8% | 27.1% | 4.3% | 0.8% | 1.0% | β90.0% | 2.1% | 1.6% | 6.5% |
| Financial health | ||||||||||
| Net debt / EBITDA | β | β | β | β | β | β | β | β | β0.7x | β0.8x |
| Debt / equity | β | β | β | 0.2x | 0.6x | 0.7x | β | β | 18.2x | 0.1x |
| Interest coverage | β | β | β | β206.2x | β21.4x | β2.6x | β15.0x | β3.0x | 3.1x | 17.1x |
| Current ratio | 3.4x | 6.4x | 4.9x | 2.0x | 2.2x | 2.4x | 1.8x | 1.9x | 2.1x | 2.4x |
| Quick ratio | 3.4x | 6.4x | 4.9x | 2.0x | 2.1x | 2.3x | 1.6x | 1.8x | 2.0x | 2.3x |
| Capital allocation | ||||||||||
| Capex / revenue | 3.9% | 3.7% | 2.5% | 2.5% | 1.2% | 0.4% | 0.4% | β | β | β |
| Stock comp / revenue | 36.0% | 133.5% | 17.3% | 15.4% | 6.7% | 6.4% | 10.3% | 7.5% | 6.9% | 4.3% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 3.0 | 3.0 | 3.0 | 4.0 | 6.0 | 2.0 | 4.0 | 7.0 | 6.0 |
| Altman Z'' | β43.3 | β24.5 | β22.8 | β28.0 | β37.0 | β22.5 | β34.0 | β38.0 | β23.8 | 0.3 |
| Accruals ratio | 8.5% | β0.4% | β9.0% | β17.7% | 17.4% | β17.1% | 10.1% | β15.4% | β9.9% | 86.0% |
Source: SEC EDGAR XBRL filings (CIK 0001034842). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
